{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:29:17Z","timestamp":1784068157615,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Research Council","award":["MR\/N019067\/1"],"award-info":[{"award-number":["MR\/N019067\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3336-1","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T11:02:52Z","timestamp":1559905372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)"],"prefix":"10.1186","volume":"20","author":[{"given":"Belinda","family":"Lennox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Yeeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9612-9401","authenticated-orcid":false,"given":"Michael","family":"Zandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly-Mee","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Tomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally-Anne","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R. E.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lingford Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram A.","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Harrower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-0760","authenticated-orcid":false,"given":"Alasdair","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"issue":"2","key":"3336_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881114563634","volume":"29","author":"O Howes","year":"2015","unstructured":"Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29(2):97\u2013115.","journal-title":"J Psychopharmacol"},{"issue":"7510","key":"3336_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421\u20137.","journal-title":"Nature"},{"issue":"10","key":"3336_CR3","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00415-014-7473-x","volume":"261","author":"E Needham","year":"2014","unstructured":"Needham E, Zandi MS. Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer\u2019s disease, traumatic brain injury and schizophrenia. J Neurol. 2014;261(10):2037\u201342.","journal-title":"J Neurol"},{"issue":"10","key":"3336_CR4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamapsychiatry.2014.1332","volume":"71","author":"GM Khandaker","year":"2014","unstructured":"Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71(10):1121\u20138.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"3336_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","volume":"61","author":"J Dalmau","year":"2007","unstructured":"Dalmau J, T\u00fcz\u00fcn E, Hy W, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D. Paraneoplastic anti\u2013N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25\u201336.","journal-title":"Ann Neurol"},{"issue":"9","key":"3336_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaneurol.2013.3216","volume":"70","author":"MS Kayser","year":"2013","unstructured":"Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70(9):1133\u20139.","journal-title":"JAMA Neurol"},{"issue":"2","key":"3336_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157\u201365.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3336_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00415-010-5788-9","volume":"258","author":"MS Zandi","year":"2011","unstructured":"Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol. 2011;258(4):686\u20138.","journal-title":"J Neurol"},{"issue":"1","key":"3336_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2215-0366(16)30375-3","volume":"4","author":"BR Lennox","year":"2017","unstructured":"Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, Lang B, Fox H, Ferry B, Scoriels L, et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry. 2017;4(1):42\u20138.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"3336_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jnnp-2016-314758","volume":"88","author":"B Lang","year":"2017","unstructured":"Lang B, Makuch M, Moloney T, Dettmann I, Mindorf S, Probst C, Stoecker W, Buckley C, Newton CR, Leite MI, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry. 2017;88(4):353\u201361.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"3336_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1017\/S0033291717002689","volume":"48","author":"F Gaughran","year":"2018","unstructured":"Gaughran F, Lally J, Beck K, McCormack R, Gardner-Sood P, Coutinho E, Jacobson L, Lang B, Sainz-Fuertes R, Papanastasiou E, et al. Brain-relevant antibodies in first-episode psychosis: a matched case-control study. Psychol Med. 2018;48(8):1257\u201363.","journal-title":"Psychol Med"},{"issue":"7","key":"3336_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/jnnp-2014-308736","volume":"86","author":"MS Zandi","year":"2015","unstructured":"Zandi MS, Paterson RW, Ellul MA, Jacobson L, Al-Diwani A, Jones JL, Cox AL, Lennox B, Stamelou M, Bhatia KP, et al. Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. J Neurol Neurosurg Psychiatry. 2015;86(7):708\u201313.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"3336_CR13","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","volume":"30","author":"EG Hughes","year":"2010","unstructured":"Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, Dalmau J, Balice-Gordon RJ. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866\u201375.","journal-title":"J Neurosci"},{"issue":"1","key":"3336_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ana.24195","volume":"76","author":"EH Moscato","year":"2014","unstructured":"Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;76(1):108\u201319.","journal-title":"Ann Neurol"},{"issue":"Pt 1","key":"3336_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/brain\/awu310","volume":"138","author":"J Planaguma","year":"2015","unstructured":"Planaguma J, Leypoldt F, Mannara F, Gutierrez-Cuesta J, Martin-Garcia E, Aguilar E, Titulaer MJ, Petit-Pedrol M, Jain A, Balice-Gordon R, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138(Pt 1):94\u2013109.","journal-title":"Brain"},{"issue":"1\u20133","key":"3336_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.schres.2014.11.001","volume":"160","author":"MS Zandi","year":"2014","unstructured":"Zandi MS, Deakin JB, Morris K, Buckley C, Jacobson L, Scoriels L, Cox AL, Coles AJ, Jones PB, Vincent A, et al. Immunotherapy for patients with acute psychosis and serum N-methyl D-aspartate receptor (NMDAR) antibodies: a description of a treated case series. Schizophr Res. 2014;160(1\u20133):193\u20135.","journal-title":"Schizophr Res"},{"issue":"3","key":"3336_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/jnnp-2018-318124","volume":"90","author":"Belinda R Lennox","year":"2018","unstructured":"Lennox BR, Tomei G, Vincent SA, Yeeles K, Pollard R, Palmer-Cooper E, Jones P, Zandi MS, Coles A. Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1). J Neurol Neurosurg Psychiatry. 2019;90:365-7.","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"2","key":"3336_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"key":"3336_CR19","unstructured":"Randomisation and online databases for clinical trials. \n                    https:\/\/www.sealedenvelope.com\/\n                    \n                  . Accessed 26 Nov 2018."},{"issue":"1","key":"3336_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","volume":"31","author":"SJ Pocock","year":"1975","unstructured":"Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103\u201315.","journal-title":"Biometrics"},{"issue":"3","key":"3336_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441\u20139.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"3336_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, Hr\u00f3bjartsson A, Mann H, Dickersin K, Berlin JA. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"3336_CR23","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hr\u00f3bjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"Pt 6","key":"3336_CR24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/brain\/awq113","volume":"133","author":"SR Irani","year":"2010","unstructured":"Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(Pt 6):1655\u201367.","journal-title":"Brain"},{"issue":"6","key":"3336_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/jnnp-2013-305218","volume":"85","author":"RW Paterson","year":"2014","unstructured":"Paterson RW, Zandi MS, Armstrong R, Vincent A, Schott JM. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry. 2014;85(6):625\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3336_CR26","unstructured":"The official home of UK legislation. \n                    http:\/\/www.legislation.gov.uk\/\n                    \n                  . Accessed 26 Nov 2018."},{"issue":"1","key":"3336_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/eip.12007","volume":"8","author":"M Birchwood","year":"2014","unstructured":"Birchwood M, Lester H, McCarthy L, Jones P, Fowler D, Amos T, Freemantle N, Sharma V, Lavis A, Singh S, et al. The UK national evaluation of the development and impact of Early Intervention Services (the National EDEN studies): study rationale, design and baseline characteristics. Early Interv Psychiatry. 2014;8(1):59\u201367.","journal-title":"Early Interv Psychiatry"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3336-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T23:13:29Z","timestamp":1591398809000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3336"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3336-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,7]]},"assertion":[{"value":"7 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MZ is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Central ethical approval has been confirmed from the South Central\u2014Oxford C Research Ethics Committee (ref approval no. 16\/SC\/0584, 06\/12\/2016) and we will not begin recruiting at other centres in the trial until local ethical approval has been obtained. The Research Ethics Committee and Health Research Authority will be notified about all substantial amendments to trial protocol and related documents. The MHRA, who are responsible for regulating medicines in the UK, have also reviewed this trial (MHRA Ref. 24551\/0028\/001-0001, 16\/01\/2017).The Informed Consent Form is approved by the REC and will be in compliance with Good Clinical Practice (GCP), local regulatory requirements and legal requirements. The investigator or designee will obtain written informed consent from each patient or the patient\u2019s legally acceptable representative before any trial-specific activity is performed. A mental health advocate may assist the participant in understanding their rights in relation to taking part in the research, if requested.The investigator will retain the original of each patient\u2019s signed Informed Consent Form.Any new information which becomes available which might affect the patient\u2019s willingness to continue participating in the trial will be communicated to the patient as soon as possible.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BL, KY, GT, RP, S-AV, MS, IC, AAH, PBJ, EJ,\u00a0L-MY, FD, TK, ALH, TH, CB, and AC have no conflict of interest. In the last 3 years, TREB has been a member of scientific advisory boards for Otsuka\/Lundbeck, Newron Pharmaceuticals and Gedeon Richter in relation to antipsychotic medication and has received speaker fees from Janssen. MZ has received honoraria for lecturing from Eisai.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"331"}}